Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) Sees Significant Decline in Short Interest

Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) saw a significant drop in short interest in the month of June. As of June 15th, there was short interest totalling 500 shares, a drop of 87.8% from the May 31st total of 4,100 shares. Based on an average daily volume of 290,100 shares, the days-to-cover ratio is presently 0.0 days.

Provectus Biopharmaceuticals Trading Down 6.6 %

Shares of PVCT traded down $0.01 during mid-day trading on Friday, reaching $0.13. 319,198 shares of the stock traded hands, compared to its average volume of 112,411. The stock has a fifty day simple moving average of $0.18 and a 200 day simple moving average of $0.15. Provectus Biopharmaceuticals has a 12-month low of $0.06 and a 12-month high of $0.22.

Provectus Biopharmaceuticals Company Profile

Provectus Biopharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis.